Companies › LTZ Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Feb 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LTZ-301 unclear - specific target not disclosed in trial registry | – | Phase 1 | Non-Hodgkin Lymphoma Refractory/ Relapsed | Feb 2028 |
| LTZ-232 | – | Phase 1 | Colorectal Cancer | Dec 2031 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07121946 | LTZ-301 | Phase 1 | Non-Hodgkin Lymphoma Refractory/ Relapsed | Oncology | Feb 2028 |
| NCT07878988 | LTZ-232 | Phase 1 | Colorectal Cancer | Oncology | Dec 2031 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.